Leap Therapeutics (NASDAQ:LPTX) Earns “Buy” Rating from HC Wainwright

Leap Therapeutics (NASDAQ:LPTX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $5.50 price target on the stock. HC Wainwright’s target price points to a potential upside of 115.69% from the stock’s current price.

Leap Therapeutics Stock Performance

Shares of LPTX stock opened at $2.55 on Thursday. Leap Therapeutics has a 52 week low of $1.68 and a 52 week high of $4.79. The stock’s fifty day moving average is $2.98 and its 200-day moving average is $2.75. The stock has a market capitalization of $97.72 million, a PE ratio of -1.32 and a beta of 0.17.

Institutional Investors Weigh In On Leap Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LPTX. Valence8 US LP bought a new position in shares of Leap Therapeutics in the 3rd quarter valued at about $48,000. HighTower Advisors LLC bought a new position in shares of Leap Therapeutics in the 3rd quarter valued at about $65,000. HB Wealth Management LLC boosted its stake in shares of Leap Therapeutics by 103.2% in the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after purchasing an additional 26,150 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Leap Therapeutics by 268.2% in the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of Leap Therapeutics in the 3rd quarter valued at about $264,000. Institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.